Lawrence Ginsberg, MD
Psychiatry · Houston, TXNPI 1851385835
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $363,615 of the $501,674 with a category attached, or 72.5%. It is spread thinly across 39 manufacturers, the largest accounting for just 17.5%. Reporting peaked in 2023 at $109,657 and has fallen 60.6% since, to $43,175 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,205 payments — averaging $227.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$88K
- Supernus Pharmaceuticals, Inc.$66K
- Alkermes, Inc.$57K
- Otsuka America Pharmaceutical, Inc.$54K
- E.r. Squibb & Sons, L.L.C.$34K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$34K
- plus $168K from 33 others
Across 370 payments — averaging $6269.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$549K
- AbbVie$495K
- F. Hoffmann-la Roche AG$220K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$206K
- Purdue Pharma L.p.$176K
- Supernus Pharmaceuticals, Inc.$123K
- plus $551K from 13 others
What the payments were for
- Consulting fees$47,1959%
- Speaking & faculty fees$363,61572%
- Travel & lodging$55,39711%
- Food & beverage$35,2887%
- Education$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$187,242
- Azstarys$85,797
- QELBREE$62,755
- ABILIFY MAINTENA$50,833
- CAPLYTA$32,113
- AUSTEDO$30,647
- VRAYLAR$25,738
- QUVIVIQ$24,082
- Jornay PM 20mg capsules (Bottle of 100)$22,069
- Dayvigo$15,903
- Dyanavel XR$15,606
- Quillivant$15,598
- Quillichew ER$15,485
- ABILIFY ASIMTUFII$13,697
- COBENFY$13,053
- JORNAY PM$9,008
- VYVANSE$6,169
- Onyda XR$5,000
- TRINTELLIX$1,276
- Equetro$1,106
How this compares
$501,674 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 16 | $199,282 |
| VraylarCariprazine Hcl | 118 | $186,947 |
| IngrezzaValbenazine Tosylate | 14 | $114,443 |
| RexultiBrexpiprazole | 28 | $48,787 |
| TrintellixVortioxetine Hydrobromide | 50 | $30,454 |
| Lisdexamfetamine Dimesylate | 109 | $25,896 |
| VyvanseLisdexamfetamine Dimesylate | 47 | $23,190 |
| CaplytaLumateperone Tosylate | 13 | $21,675 |
| Adzenys Xr-OdtAmphetamine | 20 | $17,894 |
| Aripiprazole | 59 | $16,001 |
| BelsomraSuvorexant | 27 | $11,227 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 218 | $7,089 |
| Alprazolam ErAlprazolam | 140 | $6,704 |
| Alprazolam | 472 | $4,513 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 79 | $4,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $32,404 | $199,28216 claims |
| AbbVieVraylar | $28,089 | $186,947118 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $648 | $114,44314 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $8,580 | $53,64597 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $53,916 | $48,78728 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $33,878 | $21,67513 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $732 | $17,89420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
- Prashant GajwaniHouston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.